Le Bouëdec G, De Latour M, Feillel V, Dauplat J
Centre Jean Perrin, Service de Chirurgie, Clermont-Ferrand.
J Gynecol Obstet Biol Reprod (Paris). 1990;19(7):889-94.
The authors report 22 cases of metrorrhagia occurring in the course of adjuvant hormonal therapy for breast cancer using tamoxifen. The anti-oestrogenic effect of this drug is associated with a variable agonistic effect that has been observed in organs with steroid receptors, and especially in the uterus. In this series, the cause of the abnormal bleeding is explained in 17 out of the 22 cases (ie, 3 out of 4) as a paradoxical oestrogen-like effect on the mucosa of the uterus. Two cancers of the endometrium were diagnosed.
作者报告了22例在使用他莫昔芬进行乳腺癌辅助激素治疗过程中发生的子宫出血病例。这种药物的抗雌激素作用与在具有类固醇受体的器官中观察到的可变激动作用有关，尤其是在子宫中。在该系列中，22例中的17例（即四分之三）异常出血的原因被解释为对子宫内膜的反常雌激素样作用。诊断出两例子宫内膜癌。
